Jan 6

NMDA Receptor Antagonist: Emerging therapies in CNS

Over the last few decades, the N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR) has received much attention due to their role in brain development and function. They are ionotropic receptors found in nerve cells, gets activated by binding of glutamate and glycine. NMDRs are heteromers composed of NR1 and NR2 subunits. NR2 subunits have four subtypes (A-D) in which NR2A and NR2B are predominant. NMDARs are critical to synaptic transmission, synaptic plasticity and memory function. Dysfunction in NMDAR causes several neuropathological and neurodegenerative disorders including schizophrenia, depression, tinnitus, epilepsy, neuropathic pain, Alzheimer’s disease, Huntington’s, Parkinson’s etc.

The excitotoxic NMDA receptor activation causes acute and chronic neurological disorders. This led to the discovery of many potential clinically relevant therapeutics that aims at blocking excessive NMDA activation without interfering normal NMDA functionality required for normal synaptic transmission and plasticity. To date, several drugs has been developed and tested in different clinical studies and few have achieved FDA approval. Ketamine, methadone, memantine, amantadine, and dextromethorphan are the approved NMDAR antagonist. Amongst them, Ketamine is the strong NMDAR antagonist. Despite their clinical success, these drugs pose many side effects including hallucinations, catatonia, ataxia, nightmares, and memory deficits. These drugs are also addictive that makes it difficult to use for anything that requires prolonged dosing.

Over the time, researchers and drug developers are trying to overcome these side effects. Several emerging therapeutics are in late stage development that promise to provide maximum efficacy with minimum side effects. More than 20 companies are developing drug candidates against this potential target. The major players are Johnson & Johnson (esketamine), Auris Medical (Keyzilen), NeuroRx, Inc. (Cyclurad), Avanir Pharmaceuticals (CERC 301), etc., whose drugs are in late stage of clinical development.

Jyoti Kumari
Associate Analyst

18 thoughts on “NMDA Receptor Antagonist: Emerging therapies in CNS

  1. Hey there I am so happy I found your webpage,
    I really found you by accident, while I was looking on Google for something else,
    Anyhow I am here now and would just like to say thank you for a fantastic post and a all round entertaining blog
    (I also love the theme/design), I don’t have time to read it all
    at the minute but I have bookmarked it and also included your RSS
    feeds, so when I have time I will be back to read much more, Please do keep up
    the fantastic job.

  2. Hey I am so delighted I found your blog page, I really
    found you by mistake, while I was looking on Bing for something
    else, Nonetheless I am here now and would just
    like to say cheers for a fantastic post and a all round enjoyable
    blog (I also love the theme/design), I don’t have time to go
    through it all at the moment but I have book-marked it and also included
    your RSS feeds, so when I have time I will be back to read much more, Please do keep up the superb job.

  3. Somebody еssentially assiѕt to make seriously posts I would state.

    This is the first time I frequented your web page and thus fаr?

    I surprised wіth the research yοu made to create tһis particular submit extraordinary.

    Fantastic task!

  4. I see you don’t monetize your website, don’t waste your traffic, you can earn additional cash every month because
    you’ve got high quality content. If you want to know how to make extra money, search for: Boorfe’s tips best adsense alternative

  5. It’s awesome to pay a quick visit this web page and reading the views
    of all mates concerning this post, while I am also keen of getting know-how.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.